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Abstract
Background: Many enzymes of industrial interest are not in the market since they are bio-
produced as bacterial inclusion bodies, believed to be biologically inert aggregates of insoluble
protein.
Results: By using two structurally and functionally different model enzymes and two fluorescent
proteins we show that physiological aggregation in bacteria might only result in a moderate loss of
biological activity and that inclusion bodies can be used in reaction mixtures for efficient catalysis.
Conclusion: This observation offers promising possibilities for the exploration of inclusion bodies
as catalysts for industrial purposes, without any previous protein-refolding step.
Background
Protein misfolding is a common event during bacterial
over-expression of recombinant genes [1]. The aggrega-
tion of insoluble polypeptide chains as inclusion bodies
has seriously restricted the spectrum of proteins marketed
by the biotechnology industry. Being widespreadly
believed that inclusion body proteins are biologically
inactive and therefore useless in bioprocesses, many
aggregation-prone products have been disregarded for
commercialisation. Protein solubility can be tailored by
either process [2] or protein [3] engineering, although
most efforts have been addressed to minimize inclusion
body formation by co-production of folding modulators
[4], or to refold purified inclusion body proteins by chem-
ical denaturation followed by refolding procedures [5].
Both strategies need to be adapted to particular protein
species and they render largely variable results regarding
the final soluble protein yield.
Interestingly, independent reports have noted enzymatic
activity associated to inclusion bodies formed by recom-
binant enzymes [6-8], but the extent of these side-obser-
vations has been never quantified and its biological and
biotechnological relevance remained unexplored. In this
work, we have quantitatively explored the biological
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potential use for bioprocesses in the aggregated form.
Results
To determine the occurrence of active protein in inclusion
bodies we analysed those formed upon overproduction of
the wild-type human dihydrofolate reductase (hDHFR)
and an engineered E. coli β-galactosidase fused to the
aggregation-prone foot-and-mouth disease virus (FMDV)
VP1 capsid protein (VP1LAC). In addition, we explored
fluorescence emission of green and blue fluorescent pro-
teins (GFP and BFP respectively) fused to different aggre-
gating polypeptides, namely the FMDV VP1 and a point
mutant of the human Aβ-amyloid peptide (Aβ(F19D)),
by comparing specific fluorescence emission of protein in
the soluble cell fraction and purified inclusion bodies.
Upon overproduction, all these proteins form cytoplas-
mic inclusion bodies in E. coli, the fraction of the aggre-
gated protein ranging between 28 and 88 % of the total
recombinant production (Table 1). Surprisingly, both
enzymatic activity and specific fluorescence of inclusion
body proteins were unexpectedly high (Table 1), ranging
from 6 to 166 % of that of their counterparts occurring in
the soluble cell fraction. This fact indicates that protein
inactivation mediated by in vivo aggregation is only mod-
erate. In addition, it is shown that protein packaging as
bacterial inclusion bodies into inter-molecular β-sheet
architecture (characterized by the presence of a peak
around 1620 cm-1 that dominates the FTIR spectrum in
the amide I region) [9,10] in these model proteins (Figure
1) is compatible with the functionality of enzyme active
sites and fluorophores. In this context, VP1GFP and
Aβ42(F19D)-BFP inclusion bodies are noticeably fluores-
cent inside the producing cells (Figure 2).
We wondered if active inclusion bodies could be then
used in suspension as efficient catalysts for bioprocesses.
If so, the straightforward use of these particles, that in
addition are easily removable from the reaction mixture
once the reaction is completed by low speed centrifuga-
tion, would be a convenient alternative to in vitro protein
refolding before use, a complex procedure for which effi-
ciencies are highly variable but in general low [5]. The
enzymatic activity of soluble and inclusion body versions
of both VP1LAC and hDHFR was then monitored in reac-
tion mixtures. As observed (Figure 3A and 3B), inclusion
body-embedded enzymes performed very efficiently as
catalysts of enzymatic reactions. Substrate hydrolysis
mediated by the insoluble form of VP1LAC was signifi-
cantly faster than that mediated by the same amount of
the soluble version (Figure 3A), while substrate processing
by hDHFR was slower when driven from inclusion bodies
but still important (Figure 3B). These observations are
nicely compatible with the specific activities displayed by
both versions of these proteins (Table 1).
Table 1: Enzymatic activity or fluorescence of inclusion bodies produced in E. coli
Construct name Reference Functional 
protein
Fraction of 
inclusion 
body protein 
(range, %) a
Aggregating 
domain or 
protein (all in 
the N-terminal 
position)
Specific activity or emission b 
(enzymatic units/mg or fluorescence 
units/mg)
Activity of the 
inclusion body 
fraction 
relative to that 
of soluble 
protein (%) c
Soluble protein Inclusion bodies
VP1LAC This work and 
[9]
E. coli β-
galactosidase
35.6–45.9 FMDV VP1 
capsid protein
698.3 ± 153.0 1162.5 ± 256.0 166.4
hDHFR [25] Human 
dihydrofolate 
reductase
28.4–36.8 none 8.0 10-2 ± 2.6 
10-2
4.7 10-3 ± 0.9 10-3 5.9
VP1GFP This work Green 
fluorescent 
protein
82.5–88.4 FMDV VP1 
capsid protein
359.5 ± 66.0 70.4 ± 10.1 19.5
Aβ42(F19D)-BFP [26] Blue 
fluorescent 
protein
61.4–65.3 Aβ42(F19D) 118.1 ± 10.2 36.3 ± 2.2 30.7
a The percentage of protein found in inclusion bodies relative to the total intracellular amount of recombinant protein. Values were determined 
from different samples taken at 3 and 5 h after triggering recombinant gene expression.
b These values were determined in samples taken between 3 and 5 h after triggering recombinant gene expression.
c Specific activity or fluorescence emission of inclusion bodies relative to the values determined for the soluble counterpart fraction. Protein 
amounts were determined by Western blot analysis as described and enzymatic assays performed by conventional procedures. Excitation 
wavelengths were 450 nm for VP1GFP and 360 nm for Aβ42(F19D)-BFP.Page 2 of 6
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The quantitative similarity between protein activity in the
soluble cell fraction and that of the aggregated forms of
both enzymes and fluorescent proteins (Table 1) demon-
strates that physiological aggregation as inclusion bodies
does not necessarily split protein population into active
and inactive fractions. Probably, protein solubility
(observed as the occurrence in the soluble cell fraction)
does not necessarily indicate the acquisition of a correctly
folded and thus active structure. In this context, soluble
micro-aggregates have been described [11] and recently
characterized in detail [12]. The non complete coinci-
dence between solubility and folding has been previously
indicated by exhaustive mutational analysis of model pro-
teins [13], showing that the genetic determinants of pro-
tein aggregation and misfolding are not coincident. In this
way, natively unfolded proteins are unstructured but sol-
uble [14]. Therefore, determinations of GFP-fusions solu-
bility by using fluorescence as reporter [15] could have
eventually been indicative of folding-misfolding extend
rather than solubility-insolubility, since inclusion bodies
formed by GFP fusions can be highly fluorescent (Figure
2). Furthermore, solubility does not appear to be an all-
or-nothing attribute and polypeptide chains might exhibit
a continuum of folding states in both soluble and insolu-
ble cell fractions, between which they are dynamically
transferred with the assistance of cellular folding modula-
tors [16]. In this context, the occurrence and evolution of
'soluble' aggregates in bacteria (namely misfolded species
occurring in the soluble cell fraction and presumably
inactive) [12] could explain the variable specific activity
observed in the soluble cell fraction of bacteria producing
recombinant β-galactosidases [17].
Inversely, our results prove a major occurrence of native or
native-like protein in inclusion bodies. In fact, deposition
as inclusion bodies might even result in the enrichment of
active species as suggested by the specific activity (166 %
of that found in the soluble cell fraction; Table 1) and cat-
alytic properties (Figure 3A) of VP1LAC inclusion bodies.
This observation can be then again indirectly indicative of
the presence of enzymatically inactive protein in the solu-
ble cell fraction, since protein deposition is not expected
to favour a correct folding.
Finally, although the existence of native-like structure in
bacterial inclusion body proteins has been previously
reported [18], here we demonstrate that this is not anec-
dotic but probably the architectonic nature of these kind
of aggregates, as inclusion bodies formed by four structur-
ally different proteins all display significantly high biolog-
ical activity. Interestingly, the active and properly folded
polypeptides in inclusion bodies coexist with a molecular
β-sheet organization also manifest in all cases, although
the extent of β-sheet structure and its coincidence with the
biological activity of the aggregates cannot be quantita-
tively evaluated. Since is highly improbable that enzyme
active sites involved in the intermolecular β-sheet struc-
FTIR spectra of inclusion bodies formed by either VP1LAC (black), hDHFR (green), VP1GFP (red) or Aβ42(F19D)-BFP ue) in the amide I region [9]igure 1
FTIR spectra of inclusion bodies formed by either VP1LAC 
(black), hDHFR (green), VP1GFP (red) or Aβ42(F19D)-BFP 
(blue) in the amide I region [9]. The asterisk labels the peak 
indicative of extended inter-molecular β-sheet structures in 
bacterial inclusion bodies.
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Optical micrographs of Aβ42(F19D)-BFP (top) and VP1GFP (bo tom) nclusion bodies by phase contrast (left) and fluo-rescent sc py (right)Figure 2
Optical micrographs of Aβ42(F19D)-BFP (top) and VP1GFP 
(bottom) inclusion bodies by phase contrast (left) and fluo-
rescent microscopy (right).Page 3 of 6
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activity or fluorescence are supported by properly folded
molecules or molecule segments. Aggregation, observed
as protein deposition driven by intermolecular
interactions between solvent-exposed hydrophobic
patches [9] would not necessarily disturb the conforma-
tion of all protein domains, and the active site would be
still functional if misfolded, aggregation-prone regions
are located in a distant site of the polypeptide chain. Alter-
natively, properly folded and active molecules could coex-
ist with β-sheet-enriched (inactive) versions of the same
species, and both situations could in fact take place simul-
taneously in single aggregate units. Further structural and
functional analysis would hopefully solve this issue.
From an applied point of view, inclusion bodies, being
formed by sequence-specific interaction between homol-
ogous protein patches result in highly pure protein micro-
particles [9]. Since they are also porous and highly
hydrated [19], efficient substrate diffusion would proba-
bly occur for most of the (or at least many) biotechnolog-
ically relevant aggregated enzymes, thus opening the
possibility for a new industrial market of enzymatically
active inclusion bodies.
Conclusion
Results presented here prove that aggregation of recom-
binant proteins as bacterial inclusion bodies does not nec-
essarily inactivate them, despite the enriched
intermolecular β-sheet structure observed in those formed
by the tested model proteins. The extent of protein activity
varies depending on the specific protein, but even the low-
est functional values observed are still high enough to
consider the use of inclusion body enzymes in bioproc-
esses, without any previous refolding step. The eventual
incorporation of inclusion bodies in industrial catalysis
could represent an important conceptual shift in the bio-
technology market.
Methods
Strain, plasmids and culture conditions
E. coli MC4100 [20] was used for all the experiments. Plas-
mids encoding hDHFR and Aβ42(F19D)-BFP have been
previously described and appropriate references can be
found in Table 1. Briefly, in the Aβ42(F19D)-BFP vector
(6.7 Kb) the DNA sequence encoding the 42-mer Alzhe-
imer's amyloid peptide, (bearing a Phe19→Asp mutation
to reduce its in vivo aggregation rate), is fused upstream of
the BFP gene and under the control of the T7 promoter, in
a pET-28 based vector. In the product, the two protein
sequences were separated by 12-mer linker stretch to
provide flexibility to the fusion protein and limit steric
constraints between domains. pTVP1LAC was constructed
by moving the SalI-NcoI VP1LAC fusion-encoding DNA
segment (3.5 Kb) from pJVP1LAC (8.5 Kb) to the cloning
vector pTRC99A [20]. The resulting pTVP1LAC construct
A) Product formed by soluble (black symbols) or inclusion body (red symbols) VP1LAC through ONPG hydrolysis as deter-mined at 414 nFigure 3
A) Product formed by soluble (black symbols) or inclusion body (red symbols) VP1LAC through ONPG hydrolysis as deter-
mined at 414 nm. Very coincident results have been obtained by using CPRG as alternative substrate (see the small panel), 
whose hydrolysis product was determined at 540 nm. B) Conversion of NADPH into NADP+ associated to tetrahydrofolate 
formation mediated by soluble (black symbols, left scale) and inclusion body (red symbols, right scale) hDHFR. Absorbance was 
determined at 340 nm.
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The lacZ gene was further replaced there by an appropriate
GFP-encoding DNA segment (0.7 Kb) through digestion
with EcoRI and BamHI, rendering pTVP1GFP (5.5 Kb). All
the production processes were performed in shaker-flask
cultures growing at 37°C in LB rich medium [20] plus 100
µg/ml ampicillin for plasmid maintenance, and recom-
binant gene expression was induced when the OD550
reached 0.4, by adding 1 mM IPTG. Cell samples were
taken at 3 and 5 h after induction of gene expression.
Analysis of enzymatic activity
Culture samples of 2.5 ml were jacketed in ice, disrupted
by sonication for 5 min at 50 W under 0.5 s cycles [21]
and centrifuged at 4°C for 15 min at 15000 g. The super-
natant was directly used for the analysis as the soluble cell
fraction. Inclusion bodies were purified by a detergent-
washing protocol as described [19] and used in suspen-
sion for activity analysis. β-Galactosidase activity of both
soluble cell fraction and inclusion bodies of VP1LAC was
determined in microplates as described [7,22] under con-
tinuous stirring at 250 rpm. Kinetic analysis of VP1LAC
enzymatic activity was monitored in 120 µl reaction mix-
tures with either 2 mM ONPG (pH 8.4) or 2 mM CPRG
(pH 7.0). The hDHFR activity was determined by incubat-
ing 50 µl of the protein sample and 850 µl of the appro-
priate assay buffer (0.1 M K3PO4 pH 7.4, 1 mM DTT, 0.5
M KCl, 1 mM EDTA and 20 mM ascorbic acid) for 10 min-
utes at room temperature. Then, 50 µl of 2 mM 7,8-dihid-
rofolate and 50 µl of 2 mM NADPH were added and
hDHFR activity was recorded every 15 seconds during 4
minutes at 340 nm. Protein concentration in all the assays
was adjusted between 2 and 3 µg/ml.
Fluorescence (at 510 nm for GFP and 460 nm for BFP)
was recorded in a Perkin-Elmer 650-40 fluorescence spec-
trophotometer by using excitation wavelengths of 450 nm
and 360 nm for GPF and BFP respectively. Fluorescence
was measured in 1 ml samples using dilutions when nec-
essary. Both enzymatic activities and fluorescence were
determined in triplicate.
Quantitative protein analysis
Samples of bacterial cultures (10 ml) were low-speed cen-
trifuged (15 min at 12000 g) to harvest the cells. For pro-
tein quantification in soluble cell fractions, samples were
resuspended in 400 µl of Z buffer without β-mercaptoeth-
anol [23] with one tablet of protease inhibitor cocktail
(Roche, ref. 1 836 170) per 10 ml buffer. Such mixtures,
once jacketed in ice, were sonicated for 5 min (or longer
when required to achieve a complete disruption) at 50 W
under 0.5 s cycles as described [21], and centrifuged for 15
min at 12000 g. The supernatant was mixed with denatur-
ing buffer at appropriate ratios [24]. For the determina-
tion of inclusion body protein, these structures were
purified by repeated detergent washing as described [19]
and resuspended in denaturing buffer [24]. After boiling
for 20 min, appropriate sample volumes were loaded
onto denaturing gels. For Western blot, polyclonal anti-
bodies specific for each protein were used as previously
described [17]. Dried blots were scanned at high resolu-
tion and bands quantified by using the Quantity One soft-
ware from Bio Rad, by using appropriate protein dilutions
of known concentration as controls. Determinations were
always done within the linear range and they were used to
calculate the specific activity values.
Conformational analysis by FTIR spectroscopy
For FTIR spectroscopy analysis, purified inclusion bodies
were dried for two hours in a Seepd-Vac system before
analysis to reduce water interference in the infrared spec-
tra. The FTIR spectrum of the dry samples was analysed
directly in a Bruker Tensor FTIR spectrometer. All process-
ing procedures were carried out so as to optimise the qual-
ity of the spectrum in the amide I region, between 1600
cm-1 and 1700 cm-1. Second derivatives of the amide I
band spectra were used to determine the frequencies at
which the different spectral components were located. A
general description of FTIR procedures can be found else-
where [9,10].
Abbreviations
BFP blue fluorescent protein
CPRG phenol red β-D-galactopyranoside
FMDV foot-and-mouth disease virus
FTIR fourier transform infrared
GFP green fluorescent protein
HDHFR human dihydropholate reductase
IPTG isopropyl-β-D-thiogalactopyranoside
ONPG ortho-nitrophenyl β-D-galactopyranoside
Authors' contributions
EGF performed most of the experiments and prepared the
final data and figures. NGM, A. Vera and AA analysed pro-
tein amounts by Western blot, RMF performed enzyme
kinetics, MM performed part of optical microscopy analy-
sis and SV part of FTIR analysis and data interpretation. A.
Villaverde directed the work and prepared the manuscript.
Acknowledgements
This work has been supported by BIO2004-00700 from MEC, Spain and 
2002SGR-0099 (AGAUR). EGF is recipient of a doctoral fellowship from 
MEC, Spain, and SV is supported by a "Ramón y Cajal" project awarded by 
the MCYT and co-financed by the Universitat Autònoma de Barcelona.Page 5 of 6
(page number not for citation purposes)
Microbial Cell Factories 2005, 4:27 http://www.microbialcellfactories.com/content/4/1/27Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
References
1. Baneyx F, Mujacic M: Recombinant protein folding and misfold-
ing in Escherichia coli.  Nat Biotechnol 2004, 22:1399-1408.
2. Strandberg L, Enfors SO: Factors influencing inclusion body for-
mation in the production of a fused protein in Escherichia
coli.  Appl Environ Microbiol 1991, 57:1669-1674.
3. Rinas U, Tsai LB, Lyons D, Fox GM, Stearns G, Fieschko J, Fenton D,
Bailey JE: Cysteine to serine substitutions in basic fibroblast
growth factor: effect on inclusion body formation and prote-
olytic susceptibility during in vitro refolding.  Biotechnology (N Y
) 1992, 10:435-440.
4. Baneyx F, Palumbo JL: Improving heterologous protein folding
via molecular chaperone and foldase co-expression.  Methods
Mol Biol 2003, 205:171-197.
5. Vallejo LF, Rinas U: Strategies for the recovery of active pro-
teins through refolding of bacterial inclusion body proteins.
Microb Cell Fact 2004, 3:11.
6. Tokatlidis K, Dhurjati P, Millet J, Beguin P, Aubert JP: High activity
of inclusion bodies formed in Escherichia coli overproducing
Clostridium thermocellum endoglucanase D.  FEBS Lett 1991,
282:205-208.
7. Garcia-Fruitos E, Carrio MM, Aris A, Villaverde A: Folding of a mis-
folding-prone beta-galactosidase in absence of DnaK.  Biotech-
nol Bioeng 2005, 90:869-875.
8. Worrall DM, Goss NH: The formation of biologically active
beta-galactosidase inclusion bodies in Escherichia coli.  Aust J
Biotechnol 1989, 3:28-32.
9. Carrio M, Gonzalez-Montalban N, Vera A, Villaverde A, Ventura S:
Amyloid-like properties of bacterial inclusion bodies.  J Mol
Biol 2005, 347:1025-1037.
10. Ami D, Natalello A, Gatti-Lafranconi P, Lotti M, Doglia SM: Kinetics
of inclusion body formation studied in intact cells by FT-IR
spectroscopy.  FEBS Lett 2005, 579:3433-3436.
11. Sorensen HP, Mortensen KK: Soluble expression of recom-
binant proteins in the cytoplasm of Escherichia coli.  Microb
Cell Fact 2005, 4:1.
12. de Marco A, Schroedel A: Characterization of the aggregates
formed during recombinant protein expression in bacteria.
BMC Biochem 2005, 6:10.
13. Chiti F, Taddei N, Baroni F, Capanni C, Stefani M, Ramponi G, Dob-
son CM: Kinetic partitioning of protein folding and
aggregation.  Nat Struct Biol 2002, 9:137-143.
14. Wright PE, Dyson HJ: Intrinsically unstructured proteins: re-
assessing the protein structure-function paradigm.  J Mol Biol
1999, 293:321-331.
15. Waldo GS, Standish BM, Berendzen J, Terwilliger TC: Rapid pro-
tein-folding assay using green fluorescent protein.  Nat
Biotechnol 1999, 17:691-695.
16. Carrio MM, Villaverde A: Protein aggregation as bacterial inclu-
sion bodies is reversible.  FEBS Lett 2001, 489:29-33.
17. Cazorla D, Feliu JX, Villaverde A: Variable specific activity of
Escherichia coli beta-galactosidase in bacterial cells.  Biotech-
nol Bioeng 2001, 72:255-260.
18. Oberg K, Chrunyk BA, Wetzel R, Fink AL: Nativelike secondary
structure in interleukin-1 beta inclusion bodies by attenu-
ated total reflectance FTIR.  Biochemistry 1994, 33:2628-2634.
19. Carrio MM, Cubarsi R, Villaverde A: Fine architecture of bacte-
rial inclusion bodies.  FEBS Lett 2000, 471:7-11.
20. Sambrook J, Fritsch E, Maniatis T: Molecular Cloning, A Laboratory Man-
ual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY 1989.
21. Feliu JX, Cubarsi R, Villaverde A: Optimized release of recom-
binant proteins by ultrasonication of E. coli cells.  Biotechnol
Bioeng 1998, 58:536-540.
22. Ferraz RM, Aris A, Villaverde A: Profiling the allosteric response
of an engineered beta-galactosidase to its effector, anti-HIV
antibody.  Biochem Biophys Res Commun 2004, 314:854-860.
23. Miller JH: Experiments in Molecular Genetics Cold Spring Harbor Labora-
tory Press, Cold Spring Harbor, NY 1972.
24. Laemmli UK: Cleavage of structural proteins during the
assembly of the head of bacteriophage T4.  Nature 1970,
227:680-685.
25. Davies JF, Delcamp TJ, Prendergast NJ, Ashford VA, Freisheim JH,
Kraut J: Crystal structures of recombinant human dihydro-
folate reductase complexed with folate and 5-deazafolate.
Biochemistry 1990, 29:9467-9479.
26. Sánchez de Groot N, Avilés FX, Vendrell J, Ventura S: Mutagenesis
of the central hydrophobic cluster in Ab42 Alzheimer's pep-
tide.  Simple rules to predict the aggregation propensities of
polypeptides.  submitted 2005.Page 6 of 6
(page number not for citation purposes)
